TY - JOUR T1 - ANCA-associated vasculitis JF - Clinical Medicine JO - Clin Med SP - 60 LP - 64 DO - 10.7861/clinmedicine.17-1-60 VL - 17 IS - 1 AU - Max Yates AU - Richard Watts Y1 - 2017/02/01 UR - http://www.rcpjournals.org/content/17/1/60.abstract N2 - The vasculitides are a heterogeneous group of conditions typified by their ability to cause vessel inflammation with or without necrosis. They present with a wide variety of signs and symptoms and, if left untreated, carry a significant burden of mortality and morbidity. The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are three separate conditions – granulomatosis with polyangiitis (GPA; formerly known as Wegener’s granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome). This review examines recent developments in the pathogenesis and treatment of AAV, focusing on developments in treatment following the introduction of rituximab, in particular. ER -